Benjamin Richard J 4/A
4/A · CERUS CORP · Filed Mar 10, 2026
Research Summary
AI-generated summary of this filing
Cerus (CERS) CMO Benjamin Richard Sells 125,894 Shares, Receives 55,220 Award
What Happened
- Benjamin Richard, Chief Medical Officer of Cerus Corp (CERS), received an award of 55,220 shares on March 5, 2026 (acquired at $0.00). Over March 5–9, 2026 he sold a total of 125,894 shares in three transactions, generating aggregate proceeds of approximately $250,931.
- Sales detail: 61,233 shares on 2026-03-05 at an average price reported as $2.06 ($126,299); 24,235 shares on 2026-03-06 at $2.01 ($48,603); and 40,426 shares on 2026-03-09 at $1.88 ($76,029). The award (55,220 shares) had no cash purchase price recorded in the filing.
Key Details
- Transaction dates and reported prices:
- 2026-03-05: Award 55,220 shares @ $0.00 (acquisition)
- 2026-03-05: Sale 61,233 shares, weighted avg price ~$2.06, proceeds ~$126,299
- 2026-03-06: Sale 24,235 shares @ ~$2.01, proceeds ~$48,603
- 2026-03-09: Sale 40,426 shares @ ~$1.88, proceeds ~$76,029
- Total sold: 125,894 shares for about $250,931; total acquired (award): 55,220 shares.
- Footnotes in the filing indicate some sales were non‑discretionary: portions were executed under a Rule 10b5‑1 plan and portions were to cover tax withholding tied to vesting; several sales were reported as weighted averages (price ranges or block trade) and the filer offered to provide per‑trade breakdown on request.
- Filing status: This is an AMENDED Form 4 filed March 10, 2026, covering reportable transactions from March 5–9, 2026. The filing date and amendment are noted in the document; consult the full filing for any previous version or timing details.
- Shares owned after these transactions are not listed in the information you provided (check the full Form 4 for post‑transaction holdings).
Context
- Several sales were executed under non‑discretionary arrangements (10b5‑1 and tax‑withholding instructions) — these are routine mechanisms and do not necessarily indicate a change in the insider’s view of the company. The award (55,220 shares) appears to be a grant/vesting event (reported at $0.00 in this filing). For any weighted‑average or block trade prices, the filer states they can provide a per‑trade breakdown to the issuer, shareholders, or SEC staff on request.
Insider Transaction Report
Form 4/AAmended
CERUS CORPCERS
Benjamin Richard J
Chief Medical Officer
Transactions
- Award
Common Stock
2026-03-05+55,220→ 1,004,995 total - Sale
Common Stock
[F1][F2]2026-03-05$2.06/sh−61,233$126,299→ 943,762 total - Sale
Common Stock
[F3][F4]2026-03-06$2.01/sh−24,235$48,603→ 919,527 total - Sale
Common Stock
[F1][F5]2026-03-09$1.88/sh−40,426$76,029→ 879,101 total
Footnotes (5)
- [F1]Represents shares sold pursuant to a 10b5-1 plan and does not represent a discretionary sale by the reporting person.
- [F2]Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.17 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
- [F3]Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.
- [F4]Represents a weighted average sales price. These shares were sold in a block trade per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold pursuant to such block trade.
- [F5]Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.855 to $1.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
Signature
Richard J. Benjamin, by Chrystal N. Jensen, attorney-in-fact|2026-03-10